Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesHematology/OncologyAlohaCare injectable oncology coverage / PA | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAloha CarePolicy RXMP-22

    Preferred Products Guidelines — Injectable Oncology Medications

    Customize your policy alerts

    Sign up for Aloha Care Policy RXMP-22 alerts

    Get alerted when Policy RXMP-22 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aloha Care's preferred and non-preferred injectable oncology medications (including radiopharmaceuticals) covered under the medical benefit and the criteria for when non-preferred products are medically necessary; applies to Aloha Care members subject to their benefits.

    Policy Summary
    PayerAloha Care
    PolicyPreferred Products Guidelines — Injectable Oncology Medications
    Policy CodePolicy RXMP-22
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewJan 9, 2026
    Next Review DateJan 9, 2026
    Key ActionDocument requires trial of two preferred products and physician attestation before a non-preferred oncology product is authorized.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-01-01policy effective date
    multiplepreferred for all oncology
    ~120+distinct codes listed
    HCPCS/J & Qcodes systems
    NCCN Categoriescoverage contingent on

    Coverage Criteria for Injectable Oncology Products

    Coverage for preferred and non-preferred products

    Coverage is provided as follows:

    Preferred product coverage: Coverage will be provided for preferred products contingent on the coverage criteria in the Diagnosis -Specific Criteria section.

    See Diagnosis -Specific Criteria; preferred products are listed in the Preferred Oncology products tables.

    Non-preferred product medical necessity: Treatment with the respective non-preferred product is medically necessary when BOTH: (1) history of intolerance or contraindication to two AlohaCare preferred products (unless only one preferred product exists) AND (2) physician attests that the same intolerance/contraindication/adverse event would not be expected to occur with the non-preferred product.

    Physician attestation and documentation of prior intolerance/contraindication required.

    Preferred products for oncology indications

    Covered for oncology indications as indicated in the list

    Policy Summary
    PayerAloha Care
    PolicyPreferred Products Guidelines — Injectable Oncology Medications
    Policy CodePolicy RXMP-22
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewJan 9, 2026
    Next Review DateJan 9, 2026
    Key ActionDocument requires trial of two preferred products and physician attestation before a non-preferred oncology product is authorized.
    SourceLink
    On This Page
    Coverage Criteria for Injectable Oncology ProductsApplicable HCPCS / J / Q Codes and MappingsProvider Actions, Billing and Prior Authorization GuidanceFormulary / Covered Regimens and Product ListsDefinitions and Reference ConceptsBackground and ScopePolicy Revision History
    Preferred for oncology indications: Multiple listed products in the Preferred Oncology products tables are designated as preferred for 'All oncology indications'.

    See the Preferred Oncology products tables for specific drug-to-code mappings.

    Preferred products — oncology indications

    Covered when drug and code match payer's preferred list for oncology indications

    Preferred product coverage: Drug is listed as a preferred oncology product paired with the specified HCPCS/J/Q code and intended for oncology indications (document repeatedly states 'All oncology indications').

    No additional clinical criteria are specified in these list entries; clinical eligibility follows Diagnosis -Specific Criteria and NCCN guidance.

    Preferred designation (informational)

    Preferred status and indication scope when stated

    Preferred designation: Listed products are designated as preferred for oncology use where specified; many entries explicitly state 'All oncology indications'.

    This block is informational; refer to product tables for code mappings.

    Preferred products (general coverage)

    Preferred products are listed with coverage designation in this excerpt

    Preferred-listed products: Products listed with associated codes are indicated as preferred for 'All oncology indications' where noted.

    These entries represent the payer's formulary/preferred product roster rather than discrete medical-necessity criteria.

    Preferred-product coverage

    Covered when product is one of the listed preferred agents for oncology indications

    Preferred product match: Drug administered matches one of the listed preferred products and associated codes in the Preferred Oncology products section (examples include multiple pegfilgrastim products/biosimilars, eflapegrastim, efbemalenograstim, melphalan formulations, methotrexate, pemetrexed, leuprolide/goserelin/triptorelin agents).

    Many entries are noted as 'All oncology indications'; clinical appropriateness is determined by Diagnosis -Specific Criteria and NCCN compendia alignment.

    Preferred product listing

    Preferred products for oncology:

    preferred_for_oncology: Listed agents are noted as preferred for 'All oncology indications' in multiple entries; use the specific HCPCS/J/Q code paired with the product when requesting coverage or submitting claims.

    This is a formulary/preferred product listing rather than indication-specific medical necessity criteria.

    Preferred product lists

    Preferred products for oncology-administered injectable agents

    Preferred listing: The document lists specified HCPCS/J/Q codes and product names as preferred for oncology indications; several entries explicitly note 'All oncology indications'.

    Providers should reference the listed code for the preferred product when submitting requests or claims.

    Pegfilgrastim group: Multiple pegfilgrastim branded products and biosimilars are listed as preferred (examples: Neulasta J2506; Udenyca Q5111; Fulphila Q5108; Fylnetra Q5130; Nyvepria Q5122; Stimufend Q5127; Ziextenzo Q5120).

    Pegfilgrastim-class products are enumerated across the Preferred Oncology products tables.

    Preferred products

    Preferred when included on formulary for oncology use (no additional criteria provided in this section).

    Preferred product list: The products listed are denoted as preferred oncology products; several pegfilgrastim biosimilars and melphalan/methotrexate/pemetrexed agents are included with HCPCS/J/Q codes.

    Clinical eligibility and coverage must still align with Diagnosis -Specific Criteria and NCCN recommendations.

    Preferred products (informational)

    Preferred when used for oncology indications as listed

    Preferred product list: The listed products and associated codes are designated as preferred oncology products; several entries are annotated 'All oncology indications' in the excerpt.

    Use the code-to-product mapping from the Preferred Oncology products tables when requesting coverage or billing.

    Coverage tied to NCCN evidence categories and pediatric unconditional coverage

    Covered when aligned with NCCN Categories 1 or 2A and benefit plan provisions; pediatric coverage is unconditional for chemotherapy agents:

    Primary coverage conditions: 1) Therapy is an injectable oncology medication with an indication supported by NCCN Category 1 or 2A; AND 2) Therapy indication is consistent with member benefits and Benefits Considerations.

    Therapies listed in NCCN with Category 3 evidence are considered unproved and not medically necessary per policy.

    Pediatric coverage: All chemotherapy agents for individuals under the age of 19 years for oncology indications are covered.age <19 years

    Most pediatric treatments follow national pediatric protocols similar to NCCN guidelines.

    This policy governs coverage of injectable oncology medications (including therapeutic radiopharmaceuticals) under the medical benefit using the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendia® as the evidence source. It does not provide coverage criteria for Chimeric Antigen Receptor (CAR) T‑cell products or tumor‑infiltrating lymphocyte (TIL) cell products; separate guidelines address colony stimulating factors, erythropoiesis stimulating agents, bone‑modifying agents, and antiemetics. Coverage decisions depend on member benefits and alignment with NCCN compendium recommendations and evidence categories.

    The provided excerpt does not list any explicit exclusions beyond the CAR T‑cell and TIL product exclusions noted elsewhere. Most chunks present a formulary‑style preferred product list; individual entries do not state additional product exclusions in the visible text.

    No explicit exclusions are recorded in these chunks. The content is a preferred product listing mapping drug names to HCPCS/J and Q‑codes rather than a set of excluded therapies.

    No explicit exclusions are listed in this section of the excerpt. Entries repeatedly denote products as preferred for oncology indications; exclusion language is absent.

    These portions of the document present preferred product entries (many annotated “All oncology indications”) and do not state explicit exclusions for listed agents.

    No exclusions are specified in these chunks. The text functions as a formulary/preferred products roster pairing agents with HCPCS/J/Q codes rather than an exclusions list.

    No explicit exclusions are stated in these excerpts; the material reiterates preferred product designations (including multiple pegfilgrastim biosimilars and cytotoxic agents) without exclusionary statements for those listed.

    These chunks continue the preferred products listing (pegfilgrastim group, melphalan, methotrexate, pemetrexed and others) and do not include explicit exclusions in the visible text.

    Within the policy framework, therapies in the NCCN Drugs and Biologics Compendium with Category 3 evidence are considered unproved and not medically necessary for AlohaCare coverage determinations (subject to Benefits Considerations). Additionally, the J1442 listing for filgrastim is annotated as "excluded biosimilars", indicating certain biosimilars are excluded from that specific J‑code entry.

    No additional explicit exclusions are stated in the provided portion of the document; the text primarily lists preferred products and applicable HCPCS/J/Q codes. Where exclusionary language appears, it is limited to the Category 3 compendia classification and the J1442 annotation noted above.

    The excerpt does not enumerate further explicit exclusions. Instead, it clarifies that coverage decisions rely on NCCN evidence categories (Categories 1/2A considered proven; Category 3 considered unproved and not medically necessary) and member benefits, and that pediatric chemotherapy agents (age <19 years) are covered.

    No explicit exclusions are stated in these chunks; the content is an informational preferred‑product list showing product names paired with preferred HCPCS/J‑ and Q‑codes for oncology indications.

    The policy explicitly states that therapies listed in the NCCN Drugs and Biologics Compendium with Category 3 evidence are considered unproved and not medically necessary for AlohaCare coverage determinations (see Benefits Considerations). This is the principal not‑medically‑necessary rule present in the excerpt.

    The J1442 line for filgrastim in the applicable codes list is annotated as "excluded biosimilars", which indicates that certain biosimilars are excluded from that specific J‑code listing. The document otherwise lists multiple biosimilar Q‑codes separately (e.g., Q5101, Q5110, etc.).

    These chunks do not contain explicit "not medically necessary" statements beyond the general Category 3 rule; the document is primarily a preferred products listing and coding reference in the visible text.

    No statements labeled "not medically necessary" are present in these chunks. The content repeats preferred product entries and associated codes without NMN declarations here.

    No explicit "not medically necessary" conditions are listed in these sections. The preferred products lists predominate and NMN determinations are conveyed elsewhere (e.g., NCCN Category 3 language).

    Not specified in these excerpts — the text lists preferred agents and codes; it does not provide additional NMN conditions beyond the Category 3 rule elsewhere in the document.

    No explicit "not medically necessary" statements appear in these chunks; the policy primarily enumerates preferred products and code mappings.

    These excerpts do not contain separate NMN statements; they reiterate preferred product listings and reference NCCN evidence categories which drive NMN determinations (Category 3 = not medically necessary).

    No additional "not medically necessary" claims are presented in the visible text beyond the NCCN Category 3 classification noted above, which the policy uses to identify unproved therapies for coverage decisions.

    Not specified in these chunks — the document section provides HCPCS/J/Q code descriptions and preferred product mappings; NMN conditions are not enumerated here other than the Category 3 rule referenced elsewhere.

    The excerpt does not provide other NMN conditions. The principal NMN guidance in this section is: therapies with NCCN Category 3 evidence are considered unproved and not medically necessary for AlohaCare coverage determinations.

    No new "not medically necessary" conditions are defined in these chunks. The policy relies on NCCN evidence categories to identify unproved therapies (Category 3) and otherwise lists preferred products and applicable codes.

    The policy classifies agents cited in the NCCN Drugs and Biologics Compendium with Category 3 evidence as unproved and not medically necessary for AlohaCare coverage decisions; this classification is the key NMN rule present in the provided excerpts.

    Applicable HCPCS / J / Q Codes and Mappings

    Preferred/Non-Preferred Oncology HCPCS/J-codes (sample entries)mixedCovered
    Q5107Mvasi (Bevacizumab - awwb)
    Q5118Zirabev (Bevacizumab - bvzr)
    J9035Avastin (Bevacizumab)
    J9033Bendamustine
    J9036Belrapzo (Bendamustine)
    J9041Bortezomib
    J9049Bortezomib (other code)
    Additional oncology medication codes appearing in tablesmixedCovered
    J2353Sandostatin LAR (Octreotide Depot)
    J1930Somatuline (Lanreotide)
    J0881Aranesp (Darbepoetin)
    J0885Epogen/Procrit (Epoetin alfa)
    J1442Neupogen (Filgrastim)
    Preferred HCPCS/J/Q CodesmixedCovered
    Q5110Nivestym (Filgrastim - aafi )
    Q5101Zarxio (Filgrastim - sndz)
    J1442Neupogen (Filgrastim)
    Q5148Nypozi (Filgrastim - txid)
    Q5125Releuko (Filgrastim - ayow)
    J1447Granix (TBO-filgrastim)
    J9395Faslodex (Fulvestrant)
    J9394Fulvestrant (Fresenius kabi)
    J9393Fulvestrant (Teva)
    J2353Sandostatin LAR (Octreotide Depot)
    1–10 of 22
    1/3
    Preferred HCPCS/J/Q CodesmixedCovered
    J0641Levoleucovorin
    J0642Levoleucovorin
    J0881Aranesp (Darbepoetin)
    J0885Epogen/Procrit (Epoetin alfa)
    Q5106Retacrit (Epoetin alfa - epbx)
    Q5110Nivestym (Filgrastim - aafi)
    Q5101Zarxio (Filgrastim - sndz)
    J1442Neupogen (Filgrastim)
    Q5148Nypozi (Filgrastim - txid)
    Q5125Releuko (Filgrastim - ayow)
    1–10 of 22
    1/3
    Preferred HCPCS/J/Q CodesmixedCovered
    J9395Fulvestrant (Faslodex)
    J9394Fulvestrant (Fresenius kabi)
    J9393Fulvestrant (Teva)
    J2353Sandostatin LAR (Octreotide Depot)
    J1930Somatuline (Lanreotide)
    J0640Leucovorin
    J0641Levoleucovorin
    J0642Levoleucovorin
    J9217Eligard/Lupron Depot (Leuprolide)
    J3315Trelstar (Triptorelin)
    1–10 of 23
    1/3
    Preferred HCPCS/J/Q codesmixedCovered
    J1954Leuprolide (listed multiple brands)
    J9202Goserelin (Zoladex) - oncology indications
    J9245Melphalan
    J9246Evomela (Melphalan)
    J9249Ivra (Melphalan - apotex)
    J9393Fulvestrant (Teva)
    J9394Fulvestrant (Fresenius kabi)
    J1930Somatuline (Lanreotide)
    J0641Levoleucovorin
    J0642Levoleucovorin (other)
    1–10 of 21
    1/3
    Preferred HCPCS / J / Q codes for oncology productsmixedCovered
    Q5108Fulphila (Pegfilgrastim - jmdb)
    Q5130Fylnetra (Pegfilgrastim - pbbk)
    J2506Neulasta (Pegfilgrastim)
    Q5111Udenyca (Pegfilgrastim - cbqv)
    Q5122Nyvepria (Pegfilgrastim - apgf)
    J1449Rolvedon (Eflapegrastim - xnst)
    J9361Ryzneuta (Efbemalenograstim alfa - vuxw)
    J9246Evomela (Melphalan)
    J9249Ivra (Melphalan - apotex)
    J9245Melphalan
    1–10 of 20
    1/2
    Preferred HCPCS/J/Q codesmixedCovered
    J1952Camcevi / Lupron Depot (Leuprolide)
    J1950Lupron Depot (Leuprolide)
    J1954Lutrate / Vabrinty (Leuprolide)
    J9202Zoladex (Goserelin)
    J9246Evomela (Melphalan)
    J9249Ivra (Melphalan - apotex)
    J9255Methotrexate- accord
    Q5111Udenyca (Pegfilgrastim - cbqv)
    Q5108Fulphila (Pegfilgrastim - jmdb)
    Q5130Fylnetra (Pegfilgrastim - pbbk)
    1–10 of 20
    1/2
    Preferred oncology HCPCS/J/Q codesmixedCovered
    J2506Neulasta (Pegfilgrastim)
    Q5111Udenyca (Pegfilgrastim - cbqv)
    Q5108Fulphila (Pegfilgrastim - jmdb)
    Q5130Fylnetra (Pegfilgrastim - pbbk)
    Q5122Nyvepria (Pegfilgrastim - apgf)
    J1449Rolvedon (Eflapegrastim - xnst)
    J9361Ryzneuta (Efbemalenograstim alfa - vuxw)
    Q5127Stimufend (Pegfilgrastim - fpgk)
    Q5120Ziextenzo (Pegfilgrastim - bmez)
    J3315Trelstar (Triptorelin)
    1–10 of 18
    1/2
    Preferred HCPCS/Q/J codesmixedCovered
    Q5122Nyvepria (Pegfilgrastim - apgf)
    J1449Rolvedon (Eflapegrastim - xnst)
    J9361Ryzneuta (Efbemalenograstim alfa - vuxw)
    Q5127Stimufend (Pegfilgrastim - fpgk)
    J1954Lutrate (Leuprolide)
    J9202Zoladex (Goserelin)
    J9245Melphalan
    J9246Evomela (Melphalan)
    J9249Ivra (Melphalan - apotex)
    J9260Methotrexate
    1–10 of 18
    1/2
    Preferred HCPCS/J/Q codesmixedCovered
    Q5127Ziextenzo (Pegfilgrastim - bmez)
    Q5120Ziextenzo (Pegfilgrastim - bmez) repeated
    J9202Zoladex (Goserelin)
    J9245Evomela (Melphalan)
    J9246Ivra (Melphalan - apotex)
    J9249Melphalan (unspecified)
    J9260Methotrexate
    J9255Methotrexate - accord
    J2506Neulasta (Pegfilgrastim)
    Q5111Udenyca (Pegfilgrastim - cbqv)
    1–10 of 17
    1/2
    Preferred pegfilgrastim and G-CSF product codesHCPCSCovered
    J2506Neulasta (Pegfilgrastim)
    Q5111Udenyca (Pegfilgrastim - cbqv)
    Q5108Fulphila (Pegfilgrastim - jmdb)
    Q5130Fylnetra (Pegfilgrastim - pbbk)
    Q5122Nyvepria (Pegfilgrastim - apgf)
    Q5127Stimufend (Pegfilgrastim - fpgk)
    Q5120Ziextenzo (Pegfilgrastim - bmez)
    J1449Rolvedon (Eflapegrastim - xnst)
    J9361Ryzneuta (Efbemalenograstim alfa - vuxw)
    Preferred chemotherapy and supportive agent codesHCPCSCovered
    J9245Melphalan
    J9246Evomela (Melphalan)
    J9249Ivra (Melphalan - apotex)
    J9260Methotrexate
    J9255Methotrexate- accord
    J9305Alimta (Pemetrexed)
    J9304Pemfexy (Pemetrexed)
    J9202Zoladex (Goserelin)
    J9294Pemetrexed (alternate code listed)
    J9324Pemrydi RTU (Pemetrexed)
    Preferred HCPCS/J/Q codes and productsHCPCSCovered
    J1449Ryzneuta (Efbemalenograstim alfa - vuxw)
    J9361Stimufend (Pegfilgrastim - fpgk)
    Q5127Ziextenzo (Pegfilgrastim - bmez)
    Q5120Ziextenzo (Pegfilgrastim - bmez)
    J9245Evomela (Melphalan)
    J9246Ivra (Melphalan - apotex)
    J9249Methotrexate
    J9260Methotrexate- accord
    J9255Neulasta (Pegfilgrastim)
    J2506Udenyca (Pegfilgrastim - cbqv)
    1–10 of 18
    1/2
    Applicable HCPCS/J-codes (partial list provided)mixed
    A9513Lutetium lu 177, dotatate, therapeutic, 1 millicurie
    A9590Iodine i-131, iobenguane, 1 millicurie
    A9606Radium Ra-223 dichloride, therapeutic, per microcurie
    A9607Lutetium Lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
    A9699Radiopharmaceutical, therapeutic, not otherwise classified
    J0185Injection, aprepitant, 1 mg
    J0640Injection, leucovorin calcium, 50 mg
    J0641Injection, levoleucovorin, not otherwise specified, 0.5 mg
    J0642Injection, levoleucovorin (khapzory), 0.5 mg
    J0881Injection, darbepoetin alfa, 1 mcg (non - ESRD)
    1–10 of 41
    1/5
    Radiopharmaceuticals and select supportive injectionsHCPCSCovered
    A9513Lutetium lu 177, dotatate, therapeutic, 1 millicurie
    A9590Iodine i - 131, iobenguane, 1 millicurie
    A9606Radium Ra-223 dichloride, therapeutic, per microcurie
    A9607Lutetium Lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie
    A9699Radiopharmaceutical, therapeutic, not otherwise classified
    J0185Injection, aprepitant, 1 mg
    J0640Injection, leucovorin calcium, 50 mg
    J0641Injection, levoleucovorin, not otherwise specified, 0.5 mg
    J0642Injection, levoleucovorin (khapzory), 0.5 mg
    Supportive care and growth factorsHCPCSCovered
    J0881Injection, darbepoetin alfa, 1 mcg (non - esrd)
    J0885Injection, epoetin alfa, 1000 units (non - esrd)
    J0897Injection, denosumab, 1 mg
    J1434Injection, fosaprepitant (focinvez), 1 mg
    J1442Injection, filgrastim (g - csf), excluded biosimilars, 1 mcg
    J1447Injection, tbo -filgrastim, 1 mcg
    J1449Injection, eflapegrastim - xnst, 0.1 mg
    J1453Injection, fosaprepitant, 1 mg
    J1626Injection, granisetron hydrochloride, 100 mcg
    Hormonal agents, antiemetics, growth factors, select antineoplasticsHCPCSCovered
    J1930Injection, lanreotide, 1 mg
    J1950Injection, leuprolide acetate (for depot suspension), 3.75 mg
    J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
    J3262Injection, tocilizumab, 1 mg
    J2405Injection, ondansetron hydrochloride, per 1 mg
    J2506Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
    J2562Injection, plerixafor, 1 mg
    J3315Injection, triptorelin pamoate, 3.75 mg
    J9033Injection, bendamustine hydrochloride, 1 mg
    J9035Injection, bevacizumab, 10 mg
    Antineoplastic injectables (various brands and equivalents)HCPCSCovered
    J9041Injection, bortezomib, 0.1mg
    J9054Injection, bortezomib (Boruzu), 0.1 mg
    J9171Injection, docetaxel, 1 mg
    J9245Injection, melphalan hydrochloride, not otherwise specified, 50 mg
    J9260Injection, methotrexate sodium, 50 mg
    J9292Injection, pemetrexed dipotassium, 10 mg
    J9311Injection, rituximab 10 mg and hyaluronidase
    J9355Injection, trastuzumab, 10 mg
    Biosimilars and therapeutic substitutes (Q-codes)HCPCSCovered
    Q0166Granisetron hydrochloride, 1 mg, oral, FDA approved prescription anti-emetic
    Q5101Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
    Q5106Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-ESRD use), 1000 units
    Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg
    Q5115Injection, rituximab-abbs, biosimilar, (truxima) 10 mg
    Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
    Q5123Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg
    Q5146Injection, trastuzumab-strf (Hercessi), biosimilar, 10 mg
    Oncology indication scope — 'All oncology indications'
    Scope noteSeveral products in the preferred product lists are annotated as 'All oncology indications', indicating the preference applies across oncology uses for those products.
    Examples (documented)Entries such as pegfilgrastim biosimilars (Q5108, Q5130, Q5122, Q5111, Q5127, Q5120) and agents like melphalan (J9245/J9246/J9249) are repeatedly shown with the 'All oncology indications' phrase.
    Implication for coverageWhen a product is listed as preferred for 'All oncology indications', the payer designates that product as preferred across oncology uses in this formulary list (clinical criteria may still apply elsewhere in policy).
    Radiopharmaceutical dosage references
    Millicurie dosing entriesA9513 (Lutetium Lu 177, dotatate) = 1 millicurie; A9590 (Iodine I-131, iobenguane) = 1 millicurie; A9607 (Lutetium Lu 177 vipivotide tetraxetan) = 1 millicurie.
    Per-microcurie entryA9606 (Radium Ra-223 dichloride) is listed with dose unit 'per microcurie'.
    Radiopharmaceuticals groupedRadiopharmaceutical A9699 is noted as 'Radiopharmaceutical, therapeutic, not otherwise classified' (no dose unit specified in that line).
    Dose unit listings (per mg / per mcg / per millicurie)
    Per mg examplesJ0185 (aprepitant) = 1 mg per unit as listed.
    Per mcg examplesJ0881 (darbepoetin alfa) = 1 mcg; J1442 (filgrastim - note: '1 mcg' appears with excluded-biosimilars annotation).
    Per millicurie example (radiopharmaceutical)A9513 (Lutetium Lu 177, dotatate) = 1 millicurie — dose units are presented alongside codes in the applicable codes table.

    Provider Actions, Billing and Prior Authorization Guidance

    Prior Authorization

    Prior authorization required for non-preferred oncology products

    Treatment with a non-preferred oncology product is medically necessary only when BOTH: (1) the member has a history of intolerance or contraindication to two AlohaCare preferred products (unless there is only one preferred product available) AND (2) the physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the requested non-preferred product.

    • Document history of intolerance/contraindication to two preferred AlohaCare products (unless only one preferred product exists).
    • Obtain physician attestation that the adverse event/intolerance is not expected with the non-preferred agent.
    Billing Rule

    Use listed preferred product codes for PA and billing

    When requesting coverage or submitting claims, use the HCPCS/J- or Q-code that corresponds to the AlohaCare-listed preferred product (preferred product codes are enumerated in the preferred products tables).

    • Select the listed preferred product code on prior authorization requests and claims to reflect the payer-preferred agent.
    Note

    Preferred product — HCPCS/J-/Q-code mappings listed

    Preferred products are paired with specific HCPCS/J- and Q-codes in the policy tables (examples include J1442, J1447, J2506, Q5108, Q5111, J9245, J9260 among many others); these code-to-product mappings identify the payer-preferred agents for oncology indications.

    • Refer to the policy's preferred products tables for the full list of HCPCS/J/Q codes associated with preferred agents.
    Note

    Preferred product codes enumerated (informational)

    The document lists numerous HCPCS/J/Q codes as preferred oncology products (for example J9395, J9246, J0640, Q5148, Q5125); the policy text does not add separate prior-authorization mechanics within these listing chunks.

    • Codes in the preferred list are informational but are used to identify payer-preferred agents.
    Note

    Preferred products and associated HCPCS/J-codes (annotated)

    The preferred-products tables enumerate agents and associated HCPCS/J-codes and frequently annotate entries as 'All oncology indications' for many products; these listings identify the preferred agents for oncology use though specific PA conditions are described elsewhere.

    • Many entries are annotated 'All oncology indications' — use those code mappings when billing for oncology indications.
    Note

    Preferred oncology product code listings (use for identification)

    The policy provides a preferred product roster paired with HCPCS/J- and Q-codes (e.g., multiple pegfilgrastim biosimilars and melphalan/methotrexate codes); these codes function as the payer’s preferred-product identifiers for oncology indications.

    • Use the exact HCPCS/J/Q code from the preferred-products table when documenting or billing the preferred agent.
    Billing Rule

    Use listed HCPCS/J-/Q-codes when submitting PA requests and claims

    Submit prior authorization requests and claims using the HCPCS/J- or Q-code listed beside the preferred product in the tables (selected examples include J1952, J2506, Q5111, Q5122, J9246).

    • Ensure PA forms and claims reference the code that matches the preferred product name in the policy table.
    Note

    Preferred product code list (informational)

    The document’s preferred-product sections are primarily informational code–to–product lists; the policy does not define PA criteria within each listing chunk but these codes may be implicated in utilization management.

    • Treat the code lists as the authoritative mapping of AlohaCare preferred products; check other policy sections for PA requirements.
    Note

    Preferred products — code list (reference)

    A long enumerated list pairs preferred oncology products with HCPCS/J/Q codes (pegfilgrastim biosimilars, melphalan, pemetrexed, leuprolide/goserelin entries); the chunks document the preferred codes but do not add separate PA conditions in these excerpts.

    • Reference these code listings for billing and product selection; PA conditions are covered in other policy text.
    Note

    Preferred product codes (informational — oncology)

    The policy lists preferred oncology HCPCS/J/Q codes (including multiple pegfilgrastim biosimilars, eflapegrastim, and others); these codes are identified as preferred for oncology indications though the excerpt does not impose additional PA rules here.

    • When selecting an agent for oncology use, ensure the administered product and billing code match a listed preferred entry.
    Billing Rule

    Preferred oncology product codes — use for PA and claims

    The preferred-products table identifies HCPCS/J/Q codes that AlohaCare treats as the payer-preferred identifiers for listed oncology agents; providers should reference these codes on claims and PA requests for the listed products.

    • Listing of a code does not guarantee coverage; verify coverage against Diagnosis‑Specific Criteria and benefit terms.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Formulary / Covered Regimens and Product Lists

    not_specified

    Line of therapy not specified: The excerpt does not define line-of-therapy constraints for listed products; the document primarily presents preferred product listings designated for oncology indications.

    Further sections of the full policy may define line-of-therapy requirements.

    Regimen / ListingCoverage
    Not applicable — listing of individual preferred products (supportive care and oncology supportive agents: growth factors, epoetins, bone-modifying agents, hormonal depot agents).
    This section enumerates individual preferred products rather than protocolized multi‑drug regimens; use of listed agents is governed by the preferred products guidance and applicable coverage criteria (see Diagnosis‑Specific Criteria).
    Preferred Product(s)Indication / Notes
    Multiple pegfilgrastim products (Neulasta J2506; Fulphila Q5108; Fylnetra Q5130; Nyvepria Q5122; Udenyca Q5111; Stimufend Q5127; Ziextenzo Q5120)
    Listed as preferred for 'All oncology indications' where explicitly stated in the product list; providers should bill using the listed HCPCS/J/Q code for the preferred product.
    Preferred Product(s)Indication / Notes
    Leuprolide / goserelin / triptorelin products (Camcevi J1952; Lupron J1950; Lutrate J1954; Eligard J9217; Trelstar J3315; Zoladex J9202)
    Alkylators and antimetabolites including melphalan (J9245/J9246/J9249), methotrexate (J9260/J9255), pemetrexed (J9305/J9304/J9294/J9324), and leucovorin (J0640/J0641/J0642) are listed as preferred for oncology uses.
    Preferred Agent / CodeCoverage / Indication
    Leuprolide products: Camcevi (J1952), Lupron Depot (J1950), Lutrate (J1954), Eligard (J9217); Goserelin: Zoladex (J9202)
    Melphalan formulations: Melphalan (J9245), Evomela (J9246), Ivra (J9249); Methotrexate: J9260, J9255; Pegfilgrastim originator and biosimilars (J2506, Q5111, Q5108, Q5130, Q5122, Q5127, Q5120); Eflapegrastim J1449 and other G‑CSF agents listed as preferred.
    Preferred Injectable ProductNotes / Indication
    Pegfilgrastim and pegfilgrastim biosimilars: Neulasta (J2506), Udenyca (Q5111), Fulphila (Q5108), Fylnetra (Q5130), Nyvepria (Q5122), Stimufend (Q5127), Ziextenzo (Q5120)
    Document lists these injectable agents as preferred for oncology uses; many entries are annotated 'All oncology indications' in the preferred products list.
    Preferred Product(s)Scope / Indication
    Pegfilgrastim products (J2506 and multiple Q‑codes), melphalan (J9245/J9246/J9249), methotrexate (J9260/J9255), pemetrexed (J9305/J9304/J9294/J9324), leuprolide/goserelin therapies (J1950/J1952/J1954/J9217/J9202)
    Listed as preferred for oncology use; many entries specify 'All oncology indications' in the document excerpts.
    Preferred Agent(s)Coverage / Indication
    Multiple agents including pegfilgrastim biosimilars (Q5108/Q5130/Q5122/Q5111/Q5127/Q5120), melphalan formulations (J9245/J9246/J9249), methotrexate (J9260/J9255), pemetrexed (J9305/J9304), and leuprolide/goserelin products (J1950/J1952/J1954/J9217/J9202)
    Preferred for oncology indications as listed; the product list is formulary‑style rather than a protocolized regimen.
    Formulary ProductRemarks
    Preferred oncology products (formulary listing) including multiple pegfilgrastim biosimilars, melphalan, methotrexate, pemetrexed, and hormonal depot agents.
    This is a preferred‑product formulary list and not a protocolized multi‑drug regimen; some entries are annotated 'All oncology indications'.
    Preferred Product(s)Coverage / Indication
    Pegfilgrastim products and biosimilars (J2506, Q5111, Q5108, Q5130, Q5122, Q5127, Q5120); Melphalan (J9245/J9246/J9249); Methotrexate (J9260/J9255); Pemetrexed (J9305/J9304/J9294/J9324)
    Preferred formulary listing of oncology drugs; indication details are not expanded in the excerpt beyond frequent 'All oncology indications' annotations.
    Product / HCPCS-J/Q CodePreferred Status
    Neulasta (J2506); Fulphila (Q5108); Udenyca (Q5111); Fylnetra (Q5130); Nyvepria (Q5122); Stimufend (Q5127); Ziextenzo (Q5120); Rolvedon (J1449); Ryzneuta (J9361)
    Pemetrexed products: Alimta (J9305), Pemfexy (J9304), Pemetrexed alternate (J9294), Pemrydi RTU (J9324); Melphalan J9245/J9246/J9249; Methotrexate J9260/J9255 — all listed among preferred products.
    Antiemetic Product (HCPCS)Preferred / Notes
    Aloxi (Palonosetron) IV J2469; Emend (Fosaprepitant) IV J1453; Emend (Aprepitant) PO J8501; Akynzeo IV J1454 / PO J8655; Kytril IV J1626 / PO Q0166; Zofran IV J2405 / PO Q0162
    Additional antiemetics listed: Cinvanti (Aprepitant) J0185; Focinvez (Fosaprepitant) J1434; Posfrea (Palonosetron) J2468; Sustol (Granisetron ER) J1627 — preferred antiemetic products enumerated in the document.

    Definitions and Reference Concepts

    NCCN Compendia
    Definition: NCCN CompendiaNational Comprehensive Cancer Network Drugs and Biologics Compendia® used to list appropriate drugs and biologics for specific cancers with evidence categories.
    Use in policyCoverage determinations reference NCCN Categories of Evidence and Consensus (Category 1/2A = proven; Category 3 = unproved and not medically necessary per policy).
    ScopeCompendia entries support indications and evidence-based recommendations used to inform coverage under this guideline.
    Preferred product (definition & implications)
    Preferred product (term)A 'preferred product' is a drug or biologic listed by the payer as preferred for oncology indications in the formulary-style lists.
    Provider action implicationProviders should use the listed HCPCS/J-/Q-code corresponding to the preferred product when requesting coverage or submitting claims.
    Relation to non-preferred productsNon-preferred products may require documentation of intolerance/contraindication to preferred products for medical necessity (see prior authorization rules).
    Preferred oncology products (definition)
    DefinitionPreferred oncology products: a set of drugs and associated HCPCS/J-/Q-codes designated by AlohaCare as preferred for oncology indications within this document.
    List formatThe policy presents a roster pairing drug names with HCPCS/J-/Q-codes to identify payer-preferred agents (including biosimilars).
    Operational useThese preferred product lists inform billing, claims adjudication, and potential utilization management workflows (codes are provided for reference).
    Preferred Oncology Products — roster and code mapping
    Preferred product rosterThe document enumerates oncology medications and their associated HCPCS/J-/Q-codes as the payer's preferred products for oncology indications.
    'All oncology indications' notationMany entries are annotated 'All oncology indications', signifying the preference applies broadly for oncology uses when so noted.
    Code mappingHCPCS/J-/Q-codes are provided alongside each drug name to enable accurate billing and formulary identification.
    Preferred oncology products — summary of roster
    Preferred list — summaryPreferred oncology products list includes multiple pegfilgrastim biosimilars, G-CSF agents, melphalan, methotrexate, pemetrexed, and leuprolide/goserelin agents paired with HCPCS/J-/Q-codes.
    Biosimilar identificationBiosimilars are shown with Q-codes (temporary HCPCS codes) to map therapeutic substitutes to the preferred list.
    Repetition across sectionsPreferred product entries are repeated across chunks, indicating a formulary-style consolidated preference list throughout the document.
    Preferred oncology products — medications and HCPCS/J-/Q-code mappings
    Preferred product mappingThe applicable codes table provides HCPCS/J- and A-codes alongside drug descriptions to identify preferred products for billing and formulary use.
    Examples of code mappingsExamples include J0640 (leucovorin calcium, 50 mg), J0881 (darbepoetin alfa, 1 mcg), and A9513 (Lutetium Lu 177, 1 millicurie).
    Reference only noteThe policy notes applicable codes are provided for reference; listing does not guarantee coverage or payment and other benefit rules apply.
    All oncology indications — meaning and examples
    Preference applies to oncology indicationsWhere the phrase 'All oncology indications' appears, it indicates the product is preferred across oncology uses for that agent as listed in the preferred-products sections.
    Repeated usageThe phrase 'All oncology indications' is used repeatedly across preferred product entries to denote broad oncologic applicability.
    ExamplesMultiple pegfilgrastim biosimilars (Q5108, Q5130, Q5122, Q5111, Q5127, Q5120) and agents such as melphalan (J9245/J9246/J9249) are annotated with 'All oncology indications' in the lists.
    All oncology indications — repeated phrase
    Phrase usageThe document repeatedly uses the phrase 'All oncology indications' to indicate the preference applies across oncology uses for specific products.
    Coverage interpretationWhen an entry is labeled 'All oncology indications', it denotes payer preference across the oncology indication spectrum for that product in the formulary list.
    Provider guidanceProviders should reference the paired HCPCS/J-/Q-code for the preferred product when submitting requests for oncology uses annotated this way.
    Preferred Oncology products — formulary list purpose
    Formulary list purposeAlohaCare's Preferred Oncology Products list is a formulary-style roster of oncology medications and corresponding HCPCS/J-/Q-codes used to indicate payer-preferred agents.
    Includes biosimilarsThe roster includes biosimilar Q-codes and brand mappings to identify therapeutic substitutes (e.g., Q5108 Fulphila, Q5111 Udenyca, Q5120 Ziextenzo).
    Billing and adjudicationCodes in the list are intended for use in billing, claims submission, and as the basis for utilization management where applicable (codes are for reference).
    Product code mapping — HCPCS/J-/Q-code mapping to drug names
    HCPCS/J-/Q-code presenceHCPCS/J-/Q-codes are presented alongside drug names throughout the preferred-products tables to enable accurate billing and identification of preferred agents.
    ExamplesExamples include J2506 (pegfilgrastim), J9245 (melphalan), J9305 (pemetrexed), A9513 (lutetium dotatate) and multiple Q-codes for biosimilars.
    Use noteProviders should reference these codes when selecting preferred products for prior authorization requests or claims, recognizing the list is provided for reference and other rules may apply.
    HCPCS/J/Q code — definition and examples
    HCPCS/J/Q code definedHCPCS, J- and Q-codes listed indicate the procedure/drug billing codes associated with each oncology product in the preferred lists.
    Temporary Q-codesQ-codes are used for biosimilars and therapeutic substitutes and are included to map biosimilar products to preferred listings.
    Reference examplesJ0640 (leucovorin calcium, 50 mg), J0885 (epoetin alfa, 1000 units), Q5101 (filgrastim biosimilar - zarxio, 1 mcg) appear in the applicable codes table.
    NCCN Categories — role in coverage determinations
    NCCN Categories — usageNCCN Categories of Evidence and Consensus are used to classify therapies; Category 1/2A indicate supported therapies while Category 3 is considered unproved and not medically necessary per this policy.
    Coverage tie-inCoverage decisions for injectable oncology medications reference NCCN categories and member benefit considerations.
    Pediatric exceptionAll chemotherapy agents for individuals under age 19 are covered irrespective of other limitations, per the policy's pediatric provision.
    HCPCS temporary codes for biosimilars and therapeutic substitutes
    Q-codes for biosimilarsHCPCS temporary Q-codes are used to identify biosimilar products and therapeutic substitutes in the preferred-product lists (examples: Q5108, Q5111, Q5120, Q5127).
    Mapping to brandsQ-codes are paired with biosimilar brand names (e.g., Q5108 = Fulphila; Q5111 = Udenyca; Q5120 = Ziextenzo) to support claims and documentation of the dispensed biosimilar.
    Provider implicationProviders should submit the appropriate Q-code when billing for a biosimilar to align with the preferred-product mapping in the policy.

    Background and Scope

    This guideline governs coverage of injectable oncology medications and therapeutic radiopharmaceuticals under the medical benefit using the NCCN Drugs and Biologics Compendia to establish evidence‑based indication support. Coverage for preferred products is contingent on meeting applicable coverage criteria and benefit provisions; non‑preferred products are medically necessary only when the member has documented intolerance or contraindication to two AlohaCare preferred products (unless only one preferred product exists) and the treating physician attests the same adverse event would not be expected with the requested non‑preferred agent. Pediatric chemotherapy agents (age <19 years) are covered per policy. Refer to the applicable codes table for HCPCS/J/Q mappings and note that some entries (e.g., J1442) annotate excluded biosimilars.

    Policy Revision History

    2025-12-10Adoption

    Policy adopted.

    2025-12-23Update

    Document updated (unspecified content changes).

    2026-01-09UpdateLatest

    Document updated / last revised (reflects current preferred products guidance).